This content is from: Home

Pharma deals prompt ownership questions

New deals between big pharma and academic institutions raise questions about IP ownership and patent strategies. Zöe Clyde-Watson examines how to avoid entitlement disputes

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an Managing IP subscriber? Login here


Instant access to all of our content. Membership Options | 30 Day Trial